Specific depletion of this subset of TAMs by the anti-CD163 lipid nanoparticles containing doxorubicin resulted in reduced tumor growth and increased infiltration of monocytes and immature TAMs that advance inflammatory responses and recruitment of CD4+ and CD8+ T cells promoting tumor regression. The gene discussed is CD163; the disease is neoplasm.